Neurocrine Biosciences (NBIX) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Repligen (RGEN) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 8.6% versus a gain of 1.6%. Over five years, NBIX leads with a +35.1% price change compared with -38.6% for RGEN. Neurocrine Biosciences is the larger company by market cap ($14.36 billion vs $10.40 billion), about 1.4 times the size.
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 61.8x for Repligen). Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | RGEN |
|---|---|---|
| Share price | $141.25 | $163.84 |
| Market cap | $14.36B | $10.40B |
| 1-day change | -1.55% | -2.02% |
| YTD return | -0.41% | -0.01% |
| 1-year return | +1.56% | +8.64% |
| 5-year return | +35.12% | -38.62% |
| P/E ratio (TTM) | 20.71 | 224.44 |
| Forward P/E | 11.89 | 61.84 |
| EPS (TTM) | $6.82 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.86B | $738.26M |
| Revenue growth (YoY) | +21.45% | +16.36% |
| Net income (latest FY) | $478.60M | $48.89M |
| Gross margin | 98.18% | 52.32% |
| Operating margin | 21.64% | 7.47% |
| Net margin | 16.73% | 6.62% |
| 52-week high | $186.12 | $198.87 |
| 52-week low | $122.14 | $100.99 |
| Distance from 52-week high | -24.11% | -17.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +46.75% | +18.99% |
| Average volume | 1.30M | 1.18M |
| Shares outstanding | 101.65M | 63.49M |
| Employees | 2,500 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Repligen trades at a higher earnings multiple (224.4x vs 20.7x trailing P/E).
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus 6.6 cents for Repligen.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +16.36%).
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
NBIX vs RGEN FAQ
Which is bigger, Neurocrine Biosciences or Repligen?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.36B compared with $10.40B for Repligen (RGEN).
Which stock has performed better over the past year, NBIX or RGEN?
RGEN returned +8.64% over the past 12 months, compared with +1.56% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NBIX or RGEN?
NBIX has the lower trailing P/E at 20.7, versus 224.4 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Neurocrine Biosciences and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.